A method for discovering entirely new career paths for existing clinical drugs is being exploited by start-up company Tangent Reprofiling, following a deal just signed between the company, PepTcell, the University of Warwick and Warwick spin-out company a2sp Ltd, UK. The technique, developed at the University of Warwick, enables researchers to investigate potential new uses for drugs which are already approved for clinical use.
Tangent Reprofiling, set up as a subsidiary of the immunology company PepTcell, and based in High Wycombe, Buckinghamshire, has now acquired the intellectual property which will allow it to make use of the technique.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze